retatrutide mechanism gip glp-1 glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide mechanism triple agonist glp-1
Description
Diabetes Care 33(2):428433 Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M et al (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
Patients with cardiovascular risk factors may therefore find a GLP-1RA more appropriate owing to the improvements in cardiometabolic parameters that have been observed with this drug class [10, 37, 46, 47]
Interestingly, emerging data suggest that this class of medications may have roles in othersomewhat unrelatedconditions
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Growing Awareness and Acceptance of GLP-1 Therapies There is a notable increase in awareness and acceptance of GLP-1 therapies among both healthcare professionals and patients
Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones
